Acelyrin, a drug developer for inflammatory diseases that has raised $550 million since its founding two years ago, fortified its leadership team by hiring Mina Kim as its first chief legal and administrative officer.

Kim is joining Woodland Hills, California-based Acelyrin from synthetic biotechnology company Zymergen, where she was chief legal officer and head of corporate development. The company was sold to Ginkgo Bioworks last month after pipeline setbacks wiped out nearly all its stock market value.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]